A patient developed granulomatosis with polyangiitis (GPA), a type of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), following a long-standing history of systemic lupus ...
Objective To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for treatment discontinuation and potential risk factors for subsequent ...
The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...
Objectives To define a clinically meaningful treatment response definition for haemolytic anaemia, that will form part of a novel multidomain outcome measure for SLE clinical trials.Methods An ...
The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.
Worldwide incidence and prevalence estimates of systemic lupus erythematosus (SLE) vary substantially and are influenced by ethnic and geographic differences, study design and environmental exposures ...
In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss diagnostic and treatment gaps in disease management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results